Remission rates and cost-effectiveness of OIT explained

Published

Monday, January 13, 2025 - 9:00 AM

Food allergy experts have uncovered new details into oral immunotherapy (OIT) treatment, remission rates and cost effectiveness in research published in December.

Dr Sarah Ashley and Dr Melanie Lloyd, members of the Centre for Food Allergy Research (CFAR) and National Allergy Centre of Excellence (NACE) Food Allergy Stream Advisory Group, led the studies.

Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years

Dr Ashley, who led the research published in Allergy, said OIT is a promising treatment for infants and toddlers with food allergies, but more research is needed to prove that starting OIT at a younger age increases the change of remission.

Remission is the desired outcome following OIT as it allows people to stop treatment and eat the allergen more safely and freely. Read more

Cost-effectiveness of Oral Immunotherapy for Egg Allergy According to Age of Therapy Commencement

OIT for childhood egg allergy is most cost-effective when treatment begins at age eight or older, according to new modelling.

Dr Lloyd, who led new research published in The Journal of Allergy and Clinical Immunology, said cost-effectiveness improves when the proportion of children achieving OIT-induced remission increases. Read more

See the latest research by CFAR and NACE experts on our Publications Directory.